ALS specialist NeuroSense Therapeutics Ltd announces it will be collaborating with Swiss Lonza AG to identify exosome-based biomarkers to advance theranostics in neurodegeneration.
Tag Archive for: Lonza
To improve mRNA product analysis, the Lonza Group Ltd. and Oxford Nanopore Technologies plc. are working together to develop and market a test to assess multiple critical quality attributes of mRNA products
Sotio hsd licenced Synaffix ADC platform for up to US$740m to develop up to three next generation bioconjugates.
Asher Biotherapeutics Inc has expanded its manufacturing agreement with Lonza to include the manufacturing of AB248.